Purple Biotech Ltd.

Symbol: PPBT

NASDAQ

0.67

USD

Market price today

  • -0.5709

    P/E Ratio

  • -0.0213

    PEG Ratio

  • 17.38M

    MRK Cap

  • 0.00%

    DIV Yield

Purple Biotech Ltd. (PPBT) Stock Price & Analysis

Shares Outstanding

27.92M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-0.45%

Return on Equity

-0.49%

Return on Capital Employed

-0.32%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Gil Efron CPA, M.A.
Full-time employees:20
City:Rehovot
Address:4 Oppenheimer Street
IPO:2015-11-20
CIK:0001614744

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

General Outlook

In simple terms, Purple Biotech Ltd. has 27.924 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.449% return, is a testament to Purple Biotech Ltd.'s adeptness in optimizing resource deployment. Purple Biotech Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.490%. Furthermore, the proficiency of Purple Biotech Ltd. in capital utilization is underscored by a remarkable -0.323% return on capital employed.

Stock Prices

Purple Biotech Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.7396, while its low point bottomed out at $0.68. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Purple Biotech Ltd.'s stock market.

Liquidity Ratios

Analyzing PPBT liquidity ratios reveals its financial health of the firm. The current ratio of 219.80% gauges short-term asset coverage for liabilities. The quick ratio (214.56%) assesses immediate liquidity, while the cash ratio (201.71%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio219.80%
Quick Ratio214.56%
Cash Ratio201.71%

Profitability Ratios

The effective tax rate stands at 47.73%, revealing its tax efficiency. The net income per EBT, 99.51%, and the EBT per EBIT, 166.46%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate47.73%
Net Income per EBT99.51%
EBT per EBIT166.46%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.20, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding215
Days of Payables Outstanding6544
Payables Turnover0.06

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.81, and free cash flow per share, -0.81, depict cash generation on a per-share basis. The cash per share value, 0.63, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share-0.81
Free Cash Flow per Share-0.81
Cash per Share0.63
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-56.58
Short Term Coverage Ratio-105.63
Capital Expenditure Coverage Ratio-6619.67
Dividend Paid and Capex Coverage Ratio-6619.67

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.79%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.01, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.47%, and total debt to capitalization, 1.02%, ratios shed light on its capital structure. An interest coverage of -5.47 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio0.79%
Debt Equity Ratio0.01
Long Term Debt to Capitalization0.47%
Total Debt to Capitalization1.02%
Interest Coverage-5.47
Cash Flow to Debt Ratio-56.58
Company Equity Multiplier1.30

Per Share Data

Net income per share, -0.81, reflects the portion of profit attributed to each share. The book value per share, 1.39, represents the net asset value distributed per share, while the tangible book value per share, 1.39, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-0.81
Book Value Per Share1.39
Tangible Book Value Per Share1.39
Shareholders Equity Per Share1.39
Interest Debt Per Share0.10

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 100.00%, indicates top-line expansion, while the gross profit growth, 82.09%, reveals profitability trends. EBIT growth, 1.47%, and operating income growth, 1.47%, offer insights into operational profitability progression. The net income growth, 4.54%, showcases bottom-line expansion, and the EPS growth, 28.32%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth100.00%
Gross Profit Growth82.09%
EBIT Growth1.47%
Operating Income Growth1.47%
Net Income Growth4.54%
EPS Growth28.32%
EPS Diluted Growth28.32%
Weighted Average Shares Growth33.21%
Weighted Average Shares Diluted Growth33.21%
Operating Cash Flow Growth-14.88%
Free Cash Flow Growth-13.36%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share98.75%
5-Year Operating CF Growth per Share-79.98%
3-Year Operating CF Growth per Share-11.15%
10-Year Net Income Growth per Share99.75%
5-Year Net Income Growth per Share-203.49%
3-Year Net Income Growth per Share-12.03%
10-Year Shareholders Equity Growth per Share101.21%
5-Year Shareholders Equity Growth per Share158.05%
3-Year Shareholders Equity Growth per Share-69.88%
Asset Growth-18.89%
Book Value per Share Growth-45.26%
Debt Growth-31.84%
R&D Expense Growth4.38%
SGA Expenses Growth-19.82%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 5,065,115.62, captures the company's total value, considering both debt and equity. Income quality, 0.97, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 63.30%, indicates the value of non-physical assets, and capex to operating cash flow, 0.02%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value5,065,115.62
Income Quality0.97
Intangibles to Total Assets63.30%
Capex to Operating Cash Flow0.02%
Capex to Depreciation-1.51%
Graham Number5.02
Return on Tangible Assets-122.28%
Graham Net Net0.22
Working Capital8,605,000
Tangible Asset Value6,253,000
Net Current Asset Value5,783,000
Average Payables2,832,000
Days Payables Outstanding6478
ROIC-64.13%
ROE-0.58%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.33, and the price to book ratio, 0.33, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -0.82, and price to operating cash flows, -0.57, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.33
Price to Book Ratio0.33
Price Cash Flow Ratio-0.57
Price Earnings to Growth Ratio-0.02
Enterprise Value Multiple-1.45
Price Fair Value0.33
Price to Operating Cash Flow Ratio-0.57
Price to Free Cash Flows Ratio-0.82
Price to Tangible Book Ratio0.56
Enterprise Value Over EBITDA-0.23
EV to Operating Cash Flow-0.26
Earnings Yield-103.52%
Free Cash Flow Yield-100.13%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Purple Biotech Ltd. (PPBT) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.571 in 2024.

What is the ticker symbol of Purple Biotech Ltd. stock?

The ticker symbol of Purple Biotech Ltd. stock is PPBT.

What is company IPO date?

IPO date of Purple Biotech Ltd. is 2015-11-20.

What is company current share price?

Current share price is 0.670 USD.

What is stock market cap today?

The market cap of stock today is 17379733.000.

What is PEG ratio in 2024?

The current -0.021 is -0.021 in 2024.

What is the number of employees in 2024?

In 2024 the company has 20.